Federal Register / Vol. 62, No. 180 / Wednesday, September 17, 1997 / Notices 48869

Arvada, N.A., Arvada, Colorado;

FirstBank of Aurora, N.A., Aurora,

Colorado; FirstBank of Avon, Avon,

Colorado; FirstBank of Boulder, N.A.,

Boulder, Colorado; FirstBank of

Breckenridge, N.A., Breckenridge,

Colorado; FirstBank of Douglas County,

N.A., Castle Rock, Colorado; FirstBank

of Colorado Springs, Colorado Springs,

Colorado; FirstBank of Cherry Creek,

N.A., Denver, Colorado; FirstBank of

Denver, N.A., Denver, Colorado;

FirstBank of Longmont, Longmont,

Colorado; FirstBank of Northern

Colorado, Fort Collins, Colorado;

FirstBank of Greeley, Greeley, Colorado;

FirstBank of Tech Center, N.A.,

Englewood, Colorado; FirstBank of

Colorado, N.A., Lakewood, Colorado;

FirstBank of South Jeffco, Littleton,

Colorado; FirstBank of Lakewood,

N.A.,Lakewood, Colorado; FirstBank of

Littleton, N.A., Littleton, Colorado;

FirstBank of Arapahoe County, N.A.,

Littleton, Colorado; FirstBank of

Silverthorne, N.A., Silverthorne,

Colorado; FirstBank of Vail, Vail,

Colorado; FirstBank North, N.A.,

Westminster, Colorado; FirstBank of

Wheat Ridge, N.A., Wheat Ridge,

Colorado; FirstBank of Evergreen,

Evergreen, Colorado; and FirstBank,

N.A., Palm Desert, California.

Board of Governors of the Federal Reserve

System, September 12, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–24701 Filed 9–16–97; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Agency for Health Care Policy and

Research

Contract Review Meeting

In accordance with section 10(a) of

the Federal Advisory Committee Act (5

U.S.C. Appendix 2), the Agency for

Health Care Policy and Research

(AHCPR) announces the following

technical review committee to meet

during the month of September 1997:

Name: Technical Review Committee for

the AHCPR User Liaison Program Mail Key

Support Services Contract.

Date and Time: September 24, 1997, 10

a.m.—3 p.m.

Place: Agency for Health Care Policy and

Research Willco Building, 3rd Floor

Conference Room 6000 Executive Boulevard

Rockville, MD 20852.

This meeting will be closed to the public.

Purpose: The Technical Review

Committee’s charge is to provide, on behalf

of the AHCPR Contracts Review Committee,

recommendations to the Administrator,

AHCPR, regarding the technical merit of

contract proposals submitted in response to

a specific Request for Proposals regarding the

User Liaison Program (ULP) Mail Key

Support Services contract.

The purpose of this contract is to provide

for the timely merging and mailing of letters

of invitation to User Liaison Program (ULP)

workshops through use of a ULP developed,

automated data base. The contractor will use

and maintain a data base of State legislators,

Governors and their staff, Federal and State

executive branch, and local health officials,

as well as selected public and private users

of health services research including—health

care consumers, purchasers, plans,

practitioners, and policymakers. The

contractor will perform mail merges for all

letters of invitation and mail such invitations

numbering between 3500 and 6000 as bulk

mailings. Using the data in the database, the

contractor will generate an annual User

Liaison Program Directory. These services are

required to ensure the timely dissemination

of AHCPR research findings and related

publications to the research community and

general public.

Agenda: The Committee meeting will be

devoted entirely to the technical review and

evaluation of contract proposals submitted in

response to the above referenced Request for

Proposals. The Administrator, AHCPR, has

made a formal determination that this

meeting will not be open to the public. This

action is necessary to protect the free and full

exchange of views in the contract evaluation

process and safeguard confidential

proprietary information, and personal

information concerning individuals

associated with the proposals that may be

revealed during the meeting. This action is

taken in accordance with section 10(d) of the

Federal Advisory Committee Act, 5 U.S.C.,

Appendix 2, 5 USC 522(b)(c)(6), 41 CFR 101–

6.1023 and Department procurement

regulations, 48 CFR 315.604(d).

Anyone wishing to obtain information

regarding this meeting should contact Serena

Toro, User Liaison Program, Center for

Health Information Dissemination, Agency

for Health Care Policy and Research, 2101

East Jefferson Street, Suite 401, Rockville,

Maryland 20852, 301/594–6668.

Dated: September 11, 1997.

John M. Eisenberg,

Administrator.

[FR Doc. 97–24651 Filed 9–16–97; 8:45 am]

BILLING CODE 4160–90–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Agency for Toxic Substances and

Disease Registry

Expert Workshop Regarding Medical

Monitoring in Bunker Hill, ID; Meeting

The Agency for Toxic Substances and

Disease Registry (ATSDR) announces

the following meeting.

Name: Expert Workshop Regarding

Medical Monitoring in Bunker Hill, ID.

Times and Dates: 8 a.m.–5 p.m., September

23–24, 1997.

Place: The D. Abbott Turner Center at

Emory University, 703 Clifton Road, NE,

Atlanta, GA 30329, telephone 404/712–6725.

Status: Open to the public, limited only by

the space available. The meeting room

accommodates approximately 100 people.

Purpose: ATSDR is considering the

appropriateness of medical monitoring for

populations who lived around the former

Bunker Hill lead smelting facility (the Bunker

Hill Superfund Site) in the Silver Valley area

of Idaho during a time of excess exposures

of public health significance. As Page 2 part

of this consideration process, ATSDR is

convening a series of workshops to examine

the appropriateness and feasibility of a

medical monitoring program.

The purpose of the medical monitoring

program is to provide a public health service

to communities affected by exposures to

hazardous substances. This is accomplished

by screening target populations at significant

risk of a specific health effect or outcome,

identifying individuals in need of further

diagnosis or treatment, and arranging for

appropriate referrals.

Section 104(i)(9) of the Comprehensive

Environmental Response, Compensation, and

Liability Act (CERCLA), as amended (42

U.S.C. 9604(i)(9)), provides for the

Administrator, ATSDR, to initiate a health

surveillance program for populations at

significantly increased risk of adverse health

effects as a result of exposure to hazardous

substances released from a facility. A

program included under health surveillance

is referred to as ‘‘medical monitoring or

screening’’ by ATSDR and is defined in the

legislation as ‘‘the periodic medical testing to

screen people at significant increased risk for

disease.’’

ATSDR has established criteria to

determine when medical monitoring is an

appropriate health activity and the

requirements for establishing a medical

monitoring program at a site. The legislation

requires that a mechanism to refer people for

treatment be included in the program. The

statute does not authorize ATSDR to provide

medical treatment; thus, medical monitoring

is performed as a community service, not a

health study.

ATSDR is convening three expert

workshops to assist in the evaluation of a

medical monitoring program at the Bunker

Hill site. If a program is deemed appropriate,

the Agency will develop a medical

monitoring plan for the target population(s).

The first workshop, was held on August 19–

20, 1997. This notice announces the second

workshop.

Matters to be Considered: The objective of

this workshop is to use all available relevant

data from ATSDR, including that produced

by the first workshop, to make individual

recommendations and answer questions

related to:

(1) The analysis of specific outcomes as

candidates for monitoring from the first

workshop, (2) further definition of the target

populations from the first workshop, (3) the

consideration of other heavy metals

exposures as moderators of lead-based

medical monitoring recommendations, and
48870 Federal Register / Vol. 62, No. 180 / Wednesday, September 17, 1997 / Notices

(4) medical decision analysis related to the

Bunker Hill site. Scientists with expertise

specific to the health outcomes under

consideration will convene to define

appropriate screening tests to be included in

the medical monitoring program based on the

proposed outcomes and eligible populations.

Also, the workshop will provide ATSDR

guidance in the development of clinical

evaluation protocols that could be included

in a medical monitoring program.

Agenda items are subject to change as

priorities dictate.

Contact Person for More Information:

Vivian Rush, M.D., Medical Officer, ATSDR,

Division of Health Education and Promotion,

1600 Clifton Road, NE, M/S E–33, Atlanta,

Georgia 30333, telephone 404/639–5080 or

Gregory Thomas, Senior Regional

Representative, ATSDR Region X, Seattle,

WA 98101, telephone 206/553–2113.

Dated: September 11, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 97–24637 Filed 9–16–97; 8:45 am]

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Meetings

The National Center for

Environmental Health (NCEH) of the

Centers for Disease Control and

Prevention (CDC) announces the

following Fetal Alcohol Syndrome

(FAS) Prevention meetings:

Name: 1997 Fetal Alcohol Syndrome (FAS)

Surveillance and Prevention Grantees’

Meeting.

Time And Date: 8 a.m.–5:30 p.m.,

September 25, 1997.

Place: Beaver Run Resort and Conference

Center, 620 Village Road, Breckenridge,

Colorado 80424, 970/453–6000.

Status: Open to CDC grantees conducting

FAS epidemiologic surveillance and

prevention projects among various States and

universities. Persons in the general public

wishing to participate may telephone 770/

488–7268, e-mail (GCL1@cdc.gov) or fax

(770/488–7361) their request.

Purpose: The annual meeting of CDC’s FAS

grantees is held in order to exchange

information regarding the funded projects’

activities and progress.

Matters To Be Discussed: Agenda items

include a CDC update related to FAS

epidemiologic surveillance and prevention

activities, and summary reports from each of

the grantees. Agenda items are subject to

change as priorities dictate.

Contact Person For More Information:

Gregg Leeman, Fetal Alcohol Syndrome

Prevention Section, NCEH, CDC, 4770 Buford

Highway, NE, MS:F15, Atlanta, Georgia

30341, telephone 770/488–7268, e-mail

GCL1@cdc.gov, fax 770/488–7361.

Name: Prevention and Management: Fetal

Alcohol Syndrome and Prenatal Substance

Abuse, sponsored by the Colorado Fetal

Alcohol and Substance Abuse Coalition and

CDC’s Division of Birth Defects and

Developmental Disabilities.

Times And Dates: 3 p.m.–7 p.m.,

September 25, 1997; 7:30 a.m.–5 p.m.,

September 26, 1997; 7:30 a.m.–4:30 p.m.,

September 27, 1997.

Place: Beaver Run Resort and Conference

Center, 620 Village Road, Breckenridge,

Colorado 80424, 970/453–6000.

Status: Open. Persons wishing to

participate in the conference may register by

contacting Elizabeth Franz, telephone 303/

756–8380; e-mail fasconf@aol.com; or fax

303/759–8861. The conference registration

fee is $175.00.

Purpose: Conference objectives are to

present: Effective models for identification of

and intervention with high-risk women;

current research on screening and diagnostic

methods and interventions for the child

prenatally exposed to alcohol; current public

health and epidemiological data; current

research about the effects of alcohol and

other drugs on fetal development; to discuss

policy, legal and criminal justice issues

related to FAS; and to explore communitybased prevention programs.

Matters To Be Discussed: The conference is

built around six areas of emphasis:

Intervention with high-risk women; Working

with the FAS affected child; Public health

and epidemiology; Clinical and research

issues; Policy and legal issues; Community

issues and prevention programs.

Contact Person For More Information:

Elizabeth Franz, Colorado Fetal Alcohol and

Substance Abuse Coalition Conference

Office, telephone 303/756–8380, fax 303/

759–8861, e-mail fasconf@aol.com.

Dated: September 11, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services

Office Centers for Disease Control and

Prevention (CDC).

[FR Doc. 97–24635 Filed 9–16–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Advisory Council for the Elimination of

Tuberculosis: Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following meeting.

Name: Advisory Council for the

Elimination of Tuberculosis (ACET).

Times and Dates: 8:30 a.m.–5 p.m.,

October 16, 1997; 8:30 a.m.–12 p.m., October

17, 1997.

Place: Corporate Square Office Park,

Corporate Square Boulevard, Building 11,

Room 1413, Atlanta, Georgia 30329.

Status: Open to the public, limited only by

the space available. The meeting room

accommodates approximately 100 people.

Purpose: The Council advises and makes

recommendations to the Secretary of Health

and Human Services, the Assistant Secretary

for Health, and the Director, CDC, regarding

the elimination of tuberculosis. Specifically,

the Council makes recommendations

regarding policies, strategies, objectives, and

priorities; addresses the development and

application of new technologies; and reviews

the extent to which progress has been made

toward eliminating tuberculosis.

Matters to be Discussed: Agenda items

include follow-up discussion on issues

related to isoniazid prevention therapy;

discussions on scientific basis of TB vaccine;

TB vaccine development and

implementation; economic issues relating to

TB vaccines; and developing long term goals

and/or issues of ACET. Agenda items are

subject to change as priorities dictate.

Contact Person For More Information: Janet

Cleveland, National Center for HIV, STD, and

TB Prevention, 1600 Clifton Road, NE, M/S

E–07, Atlanta, Georgia 30333, telephone 404/

639–8008.

Dated: September 11, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 97–24636 Filed 9–16–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0022]

Agency Information Collection

Activities; Submission for OMB

Review; Comment Request

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that the proposed collection of

information listed below has been

submitted to the Office of Management

and Budget (OMB) for review and

clearance under the Paperwork

Reduction Act of 1995 (the PRA).

DATES: Submit written comments on the

collection of information by October 17,

1997.

ADDRESSES: Submit written comments

on the collection of information to the

Office of Information and Regulatory

Affairs, OMB, New Executive Office

Bldg., 725 17th St. NW., rm. 10235,

Washington, DC 20503, Attention: Desk

Officer for FDA.

FOR FURTHER INFORMATION CONTACT:

Judith V. Bigelow, Office of Information